Cancer vaccine breakthrough: Moderna, Merck’s mRNA shot cuts melanoma return and spread

A personalized cancer vaccine from Moderna and Merck has delivered one of the most important clinical results yet for mRNA technology outside infectious diseases, reducing the risk of high-risk melanoma returning and spreading when added to Merck's immunotherapy Keytruda.